Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.66 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918765 | 1.00 | SCN8A (0.66) | SCN8ASCN10A | |
| SCHEMBL16408284 | 0.97 | — | — | |
| SCHEMBL17791106 | 0.91 | — | — | |
| SCHEMBL16398467 | 0.91 | — | — | |
| SCHEMBL29919175 | 0.90 | SCN8A (0.66) | SCN8ASCN10A | |
| SCHEMBL19547948 | 0.90 | — | — | |
| SCHEMBL16398786 | 0.90 | SCN8A (0.66) | SCN8ASCN10A | |
| SCHEMBL16408286 | 0.87 | — | — | |
| SCHEMBL16408285 | 0.87 | — | — | |
| SCHEMBL16408243 | 0.87 | SCN8A (0.64) | SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-21 | — | — | US | claimed |
| EP-3022175-B1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | claimed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4346818-B1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4347031-B1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-06-02 | — | — | US | disclosed |
| EP-3022175-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20160009743-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2016-01-14 | — | — | US | disclosed |
| US-9163042-B2 | Prodrugs of pyridone amides useful as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-20 | — | — | US | disclosed |
| WO-2015089361-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150166589-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015010065-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | SCN8A 1/4885SCN10A 22/4885 |
| US-20160009743-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | TRPV1, P2RY1, P2RX3 | SCN8A 70/4885SCN10A 32/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | SCN8A 26/4885SCN10A 37/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | SCN8A 56/4885SCN10A 94/4885 |
| US-20150166589-A1 | PRODRUGS OF PYRIDONE AMIDES USEFUL AS MODULATORS OF SODIUM CHANNELS | TRPV1, P2RY1, P2RX3 | SCN8A 70/4885SCN10A 32/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | SCN8A 17/4885SCN10A 10/4885 |
| US-11203571-B2 | Sulfonamides as modulators of sodium channels | TRPV1, SCN1A, SCN5A | SCN8A 24/4885SCN10A 7/4885 |
| US-20160152561-A1 | SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, SCN5A | SCN8A 24/4885SCN10A 7/4885 |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | SCN8A 15/4885SCN10A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.